Articles related to Oncology, Medical

In this 15-minute CME activity, two experts provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma.

In an interim look at the SKYSCRAPER-01 study, investigators found tiragolumab plus atezolizumab didn’t meaningfully slow tumor progression compared to atezolizumab alone in patients with advanced, newly diagnosed non-small cell lung cancer (NSCLC). Tiragolumab has now fallen short in two phase 3 lung cancer trials, having already missed its study objectives in advanced SCLC earlier this year.

A phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in patients with unresectable stage III NSCLC and no progression after concurrent chemoradiotherapy. With a median follow-up of 11.5 months, both combinations increased ORR and prolonged PFS versus durvalumab alone. Safety was similar across arms with no new or significant safety signals identified with either combination.

Here are some highly rated but lesser-known restaurants the locals like: Less than a mile from McCormick Place is the Chinese fusion restaurant Go 4 Food. Try the Sweet and Sour Chinese-Style Ribs, the succulent Walnut Shrimp, or the spicy Chili Fusion Dungeness Crab with some Millionaire-Style Fried Rice A 10-minute drive down S. Riverside Drive yields Norman’s Bistro, featuring American creole cuisine If you are up to the 20-minute ride to Lincoln Park, the locals say Toro Sushi is the spot for sushi in Chicago Within 15 minutes of the convention center are these top-rated choices: Chicago Firehouse (American) Avec Restaurant (Mediterranean) Monteverde Restaurant & Pastificio (Italian) And if you have time before dinner, this unique museum is in the same area, just off the Magnificent Mile.

Overall, NGS-based MRD analysis in ALL seems to be especially helpful in patients with RQ-PCR+ MolNE and may help to discriminate true MRD from false positivity in this considerable and clinically important group.

In this interview, Nicole Lamanna, MD, discusses challenges and application of BTK inhibitors, results with pirtobrutinib in hematologic malignancies, specifically addressing CLL, and shares her personal observations regarding pirtobrutinib use.